Sermorelin for Women: Menopause, Sleep, Body Composition

Key takeaways

• Sermorelin raises growth hormone in women as in men, but in the only placebo-controlled GHRH-analog trial that enrolled women (10 women and 9 men aged 55 to 71, 16 weeks) the benefits went to the men: lean mass, insulin sensitivity, well-being and libido improved in men only, and sleep did not change in either sex.
• There is no sermorelin trial for menopause symptoms, skin, weight loss or hormone balancing in women, and GHRH impaired sleep in laboratory studies of healthy women.
• The trial doses that moved hormones were 1 to 2 mg a day; telehealth prescriptions of 200 to 500 mcg nightly are several times lower and have no controlled data.
• Pregnancy, breastfeeding, an active or recent cancer (including breast and other hormone-sensitive cancers) and uncontrolled diabetes rule it out. IGF-1 and glucose are the labs to watch, and oral estrogen lowers IGF-1, which confuses the monitoring.
• For the goals women name, the evidence lives elsewhere: hormone therapy for menopause, cognitive behavioral therapy for insomnia, GLP-1 drugs and resistance training for body composition.

Sermorelin is prescribed to women for menopause, sleep and body composition, and the trials support none of the three. The one placebo-controlled trial of a GHRH analog that enrolled women found that growth hormone rose in both sexes but that lean mass, insulin sensitivity, well-being and libido improved only in the men, and that sleep changed in no one; there is no sermorelin trial in menopausal women at all. The sermorelin profile covers the compound in full, PT-141 for women covers the other peptide sold to women, and peptides for menopause ranks what has evidence.

What the trials found in women

Almost every adult sermorelin study enrolled men only. The exception, and the best-designed adult trial, enrolled 10 women and 9 men aged 55 to 71 and gave them four weeks of placebo followed by 16 weeks of a stabilized GHRH analog, [Nle27]GHRH(1-29)-NH2, at 10 micrograms per kilogram nightly, measuring overnight growth hormone, IGF-1, body composition, insulin sensitivity, skin thickness and quality of life, including sleep (Khorram 1997).

The authors concluded that the analog "induced anabolic effects favoring men more than women" and called for studies to explain the difference; none were done. Grade B for raising growth hormone in women, D for every outcome a woman is told she will notice.

Sleep is the claim with evidence against it. GHRH increases slow-wave sleep in young men. In women it does the opposite: an earlier study of women aged 19 to 76 found that GHRH impaired sleep, and a follow-up in healthy young women tested on days 4 to 6 of the menstrual cycle found that pulsed intravenous GHRH reduced REM sleep at the lower dose and stage 4 sleep at the higher dose; the authors wrote that the study "confirms that systemic GHRH impairs sleep in women" (Mathias 2007). No sermorelin trial with objective sleep measures in women exists; the only relevant data point the wrong way.

What has no data in women

• Menopause symptoms. No trial of sermorelin or any GHRH analog has measured hot flashes, night sweats, vaginal symptoms or mood at menopause; it raises growth hormone and IGF-1, not estrogen or progesterone.
• Skin beyond thickness, and hair. Caliper thickness rose in both sexes; wrinkles, elasticity and hair were never measured.
• Weight loss. Weight and fat mass did not change in either sex; adding sermorelin to a GLP-1 to protect muscle has no trial behind it.
• Before-and-after results. No published images or body-composition series exist for women; progress photos on clinic pages are marketing.
• Long-term safety. The longest trial in women is 16 weeks; the sermorelin profile covers what growth hormone itself did to healthy older adults.

Studied doses versus clinic doses

There is no sermorelin dosage for women in the literature. The trial with women dosed by weight, about 650 mcg a night for a 65 kg woman; the men's studies used 1 to 2 mg a day, and the next step down from the lowest effective dose did nothing. A 300 mcg prescription is two to seven times lower than any dose that moved a hormone in a trial. Ask a clinician which IGF-1 change they expect and when they will measure it.

Units at common concentrations

A 6 mg vial reconstituted with 3 mL gives 2 mg/mL; a 9 mg vial with 3 mL gives 3 mg/mL. Units on a U-100 insulin syringe equal the dose in mcg divided by the concentration in mcg/mL, times 100.

Run your own numbers in the reconstitution calculator and the units guide, and trust the pharmacy label if it disagrees.

Who should not use it

• Pregnancy and breastfeeding. Not studied; do not use. Irregular perimenopausal cycles are not contraception.
• Active or recent cancer, including breast and other hormone-sensitive cancers. Growth hormone and IGF-1 are growth signals: in a pooled analysis of 17 prospective studies with 4,790 breast cancer cases, women in the highest fifth of circulating IGF-1 had 28% higher odds of breast cancer than those in the lowest fifth, confined to estrogen-receptor-positive tumors and unchanged by menopausal status (EHBCCG 2010). That is observational, not a sermorelin trial, and reason enough not to raise IGF-1 on purpose after breast, endometrial or ovarian cancer without an oncologist's sign-off.
• Diabetes. Growth hormone opposes insulin. Fasting glucose did not change over 16 weeks in the trial with women, but uncontrolled diabetes or diabetic retinopathy rules sermorelin out, and prediabetes calls for glucose monitoring.
• Untreated hypothyroidism, ongoing glucocorticoid treatment, a known pituitary disorder, or a prior hypersensitivity reaction to sermorelin or GHRH.

What to monitor, and the oral-estrogen trap

A reasonable plan is a baseline IGF-1, fasting glucose or HbA1c and a basic metabolic panel; a repeat IGF-1 and glucose at 8 to 12 weeks; then every three to six months, stopping the drug if IGF-1 has not moved. The only adverse effect in the trial with women was a transient rise in lipids, so a lipid panel at follow-up is sensible (Khorram 1997).

For women on hormone therapy there is a complication no clinic page mentions. Oral estrogen, but not transdermal estrogen, impairs the action of growth hormone in the liver and lowers IGF-1 production, enough to cause a loss of lean tissue and a gain of fat in postmenopausal women (Leung 2004). A woman taking an estradiol tablet will therefore show a low IGF-1 for a reason that has nothing to do with her pituitary, and a clinician who prescribes sermorelin to correct it is treating an artifact of the estrogen route. No trial has combined sermorelin with hormone therapy; if both are prescribed, IGF-1 should be read with the route in mind, and switching from oral to transdermal estrogen will change it on its own.

The honest comparison

Cost and how to get it

Compounded sermorelin runs $150 to $400 a month through telehealth as of October 2026, with baseline labs adding $150 to $400 in the first month; see the cost guide. It is legally compoundable, which separates it from most peptides sold to women. A legitimate prescription comes from a clinician licensed in your state, names the 503A pharmacy, includes a baseline IGF-1 and sets a date to repeat it.

Bottom line

Sermorelin does in women what it does in men at the level of the hormone: growth hormone rises. Below that, the one trial that compared the sexes found the benefits went to the men, sleep improved for no one, and GHRH impaired sleep when women were studied in the laboratory. Nothing about menopause has been tested. A woman with a documented low IGF-1, read with her estrogen route in mind and prescribed by a clinician who will measure it again, has a defensible reason to try it. A woman buying it for hot flashes, sleep or a flatter stomach is paying for a result the evidence does not contain.

Frequently asked questions

+−Is sermorelin good for women?

It raises growth hormone in women as it does in men, but in the only placebo-controlled GHRH-analog trial that enrolled women (10 women and 9 men aged 55 to 71, treated for 16 weeks) the benefits went to the men: lean mass, insulin sensitivity, well-being and libido improved in men only, skin thickness rose in both sexes, and sleep did not change in either. It is legally compoundable and costs $150 to $400 a month. A woman considering it should know that the trial evidence for women is a negative result for everything except the hormone level.

+−What does sermorelin do for a woman's body?

It makes the pituitary release more growth hormone overnight, and IGF-1 rises for a few weeks before drifting back toward baseline. In the 16-week trial, that produced thicker skin by caliper and nothing else measurable in women: no change in lean mass, fat, bone density, insulin sensitivity, weight, blood pressure or sleep. It does not raise estrogen or progesterone and does not treat menopause.

+−What is the sermorelin dosage for women?

No dose has been studied in women specifically. The one trial with women dosed by body weight at 10 micrograms per kilogram nightly, about 650 mcg for a 65 kg woman; the trials in men used 1 to 2 mg a day, and 0.5 mg twice daily did nothing. Telehealth prescriptions of 200 to 500 mcg nightly are below every dose that moved a hormone in a trial and have no controlled data. These are studied doses, not recommendations; the pharmacy label decides the dose.

+−Does sermorelin help with menopause?

No. No trial of sermorelin or any growth hormone secretagogue has measured hot flashes, night sweats, vaginal symptoms or menopausal mood. Sermorelin raises growth hormone, not estrogen. Menopausal hormone therapy is the most effective treatment for vasomotor and genitourinary symptoms and prevents bone loss; a clinic selling sermorelin for menopause is selling something with no trial behind it in place of something with decades of them.

+−What should a woman expect from sermorelin before and after?

In hormone terms, higher overnight growth hormone from the first injection and a rise in IGF-1 within two weeks that may fade with continued use. In outcome terms, the trial that enrolled women found no change in weight, fat, lean mass, sleep or well-being over 16 weeks. There are no published before-and-after photos or body-composition series of women on sermorelin; the images on clinic pages are marketing, not data.

+−Can you take sermorelin with HRT?

No trial has combined them, so there is no safety or benefit data. The known issue is a laboratory one: oral estrogen lowers IGF-1 through its first-pass effect on the liver, while transdermal estrogen does not, so a woman on an estradiol tablet will read low on the IGF-1 test sermorelin is monitored with. If both are prescribed, the same clinician should manage them and interpret IGF-1 with the estrogen route in mind.

+−Does sermorelin cause weight loss in women?

No. Body weight and fat mass did not change in women or men over 16 weeks of a GHRH analog, and no sermorelin trial has shown weight loss in anyone. The visceral-fat data belong to tesamorelin, a different GHRH analog, in HIV-associated lipodystrophy. For weight, GLP-1 drugs have the evidence, and they work after menopause.

+−What are the side effects of sermorelin in women?

The common ones are injection-site redness, swelling or pain, flushing, headache, dizziness and nausea. In the 16-week trial with women, the only adverse effect was a transient rise in blood lipids that resolved by the end of the study, with no change in blood pressure, weight or fasting glucose. The long-term risks of raising growth hormone and IGF-1 for years, including fluid retention, joint pain, impaired glucose tolerance and a theoretical effect on hormone-sensitive cancers, have not been studied in women.

Sources

1. StudyKhorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]GHRH-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997;82:1472-9. (1997)
2. StudyMathias S et al. Systemic growth hormone-releasing hormone (GHRH) impairs sleep in healthy young women. Psychoneuroendocrinology 2007;32:1021-7. (2007)
3. StudyCorpas E et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and IGF-I levels in old men. J Clin Endocrinol Metab 1992;75:530-5. (1992)
4. StudyVittone J et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism 1997;46:89-96. (1997)
5. ReviewLeung KC, Johannsson G, Leong GM, Ho KK. Estrogen regulation of growth hormone action. Endocr Rev 2004;25:693-721. (2004)
6. StudyEndogenous Hormones and Breast Cancer Collaborative Group; Key TJ, Appleby PN, Reeves GK, Roddam AW. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 2010;11:530-42. (2010)
7. GuidelineThe 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022;29:767-94. (2022)
8. StudyMcCurry SM et al. Telephone-based cognitive behavioral therapy for insomnia in perimenopausal and postmenopausal women with vasomotor symptoms: a MsFLASH randomized clinical trial. JAMA Intern Med 2016;176:913-20. (2016)